Full Press Release Details
BiondVax Announces Third Quarter 2020
Financial Results & Business Update
Jerusalem, Israel - January 28, 2021
- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and
ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced
its third quarter financial results for the quarter ended September 30, 2020.
Third Quarter 2020 Financial Summary
in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September
income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NIS 19.0
million for the third quarter of 2019.
30, 2020, BiondVax had cash and cash equivalents of NIS 24.8 million (approximately $7.2 million) compared to NIS 72.5 million
as of December 31, 2019. At the currently anticipated burn rate going forward, BiondVax has sufficient funds to continue operations
through the end of Q2 2021.
BiondVax Pharmaceuticals Ltd. (NASDAQ:
BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention
of infectious diseases and related illnesses. The Company had been developing M-001, a novel flu vaccine candidate that was designed
to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase
1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in
stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial
of M-001 which failed to meet the trial's primary and secondary efficacy endpoints. The company is now pursuing opportunities
in the infectious disease space, including exploring several alternatives for development of a pipeline of assets. For more information,
please visit www.biondvax.com.
Joshua E. Phillipson | +972 8 930
2529 | j.phillipson@biondvax.com
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe,"
"intend," "plan," "continue," "may," "will," "anticipate,"
and similar expressions are intended to identify forward-looking statements, including statements regarding future business strategies
that BiondVax may explore. These forward-looking statements reflect the management's current views with respect to certain
current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ
materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not
limited to, that BiondVax does not have sufficient cash to operate its business for the next 12 months, which raises substantial
doubt about its ability to continue as a going concern; the risk that BiondVax may not be able to secure capital on attractive
terms, if at all; the risk that BiondVax is currently exploring new business strategies after its M-001 universal flu vaccine candidate
failed to meet the Phase 3 trial's primary and secondary efficacy endpoints; the risk that the European Investment Bank may
accelerate the loans under its finance contract with BiondVax; the risk that BiondVax may not execute a strategic alternative to
M-001; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product
opportunities; BiondVax's ability to enter into collaborations on terms acceptable to us or at all; receipt, if and
when provided, of regulatory approval of BiondVax's manufacturing facility in Jerusalem; the risk that drug development involves
a lengthy and expensive process with uncertain outcomes; and the ability of the Company to maintain, preserve and defend its intellectual
property and patents granted. More detailed information about the risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2019 and
other filings filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov.
The Company undertakes no obligation to revise or update any forward-looking statement for any reason.
In thousands, except share and per share data
| Convenience | ||||||||||||||||
| Translation | ||||||||||||||||
| December 31, | September 30, | September 30, | ||||||||||||||
| 2019 | 2019 | 2020 | 2020 | |||||||||||||
| Audited | Unaudited | Unaudited | ||||||||||||||
| N I S | U.S. dollars | |||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||
| Cash and cash equivalents | 72,467 | 75,247 | 24,774 | 7,200 | ||||||||||||
| Other receivables | 656 | 1,887 | 2,930 | 851 | ||||||||||||
| 73,123 | 77,134 | 27,704 | 8,051 | |||||||||||||
| LONG-TERM ASSETS: | ||||||||||||||||
| Property, plant and equipment | 34,981 | 34,324 | 39,889 | 11,592 | ||||||||||||
| Right-of-use assets | 7,136 | 7,371 | 6,433 | 1,870 | ||||||||||||
| Other long-term assets | 510 | 507 | 891 | 259 | ||||||||||||
| 42,627 | 42,202 | 47,213 | 13,721 | |||||||||||||
| - | ||||||||||||||||
| 115,750 | 119,336 | 74,917 | 21,772 | |||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||
| Trade payables | 17,062 | 1,552 | 8,213 | 2,387 | ||||||||||||
| Operating lease liabilities | 694 | 697 | 653 | 190 | ||||||||||||
| Other payables | 1,203 | 820 | 2,289 | 665 | ||||||||||||
| 18,959 | 3,069 | 11,155 | 3,242 | |||||||||||||
| LONG-TERM LIABILITIES: | ||||||||||||||||
| Liability in respect of government grants | 14,812 | 14,454 | - | - | ||||||||||||
| Operating lease liabilities | 6,809 | 6,898 | 6,268 | 1,821 | ||||||||||||
| Loan from others | 123,780 | 108,353 | 59,242 | 17,217 | ||||||||||||
| Warrants | 16,354 | 6,908 | - | - | ||||||||||||
| Severance pay liability, net | 89 | 87 | 93 | 27 | ||||||||||||
| 161,844 | 136,700 | 65,603 | 19,065 | |||||||||||||
| SHAREHOLDERS' EQUITY: | ||||||||||||||||
| Ordinary shares of no par value: Authorized: 600,000,000 shares at September 30, 2020 and 2019 (unaudited) and December 31, 2019; Issued and outstanding: 461,451,767, 460,822,640 and 402,351,657 shares at September 30, 2020 and 2019 (unaudited) and December 31, 2019, respectively | *)- | *)- | *)- | *)- | ||||||||||||
| Share premium | 255,285 | 256,889 | 308,855 | 89,757 | ||||||||||||
| Accumulated deficit | (320,338 | ) | (277,322 | ) | (310,696 | ) | (90,292 | ) | ||||||||
| (65,053 | ) | (20,433 | ) | (1,841 | ) | (535 | ) | |||||||||
| 115,750 | 119,336 | 74,917 | 21,772 |
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
In thousands, except share and per share data
| Convenience translation | ||||||||||||||||||||||||
| Nine months | ||||||||||||||||||||||||
| Year ended | Three months ended | Nine months ended | ended | |||||||||||||||||||||
| December 31, | September 30, | September 30, | September 30, | |||||||||||||||||||||
| 2019 | 2019 | 2020 | 2019 | 2020 | 2020 | |||||||||||||||||||
| Audited | Unaudited | Unaudited | ||||||||||||||||||||||
| N I S | U.S. dollars | |||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Research and development, net of participations | 68,645 | 16,133 | 12,579 | 37,037 | 43,595 | 12,668 | ||||||||||||||||||
| Marketing, general and administrative | 9,706 | 2,790 | 7,303 | 8,741 | 12,423 | 3,610 | ||||||||||||||||||
| Other income | - | - | 75,485 | - | 75,485 | 21,937 | ||||||||||||||||||
| Total operating income (expenses) | (78,351 | ) | (18,923 | ) | 55,603 | (45,778 | ) | 19,467 | 5,657 | |||||||||||||||
| Operating gain (loss) | (78,351 | ) | (18,923 | ) | 55,603 | (45,778 | ) | 19,467 | 5,657 | |||||||||||||||
| Financial income | 4 | 169 | - | 193 | 5,034 | 1,463 | ||||||||||||||||||
| Financial expense | (30,847 | ) | (601 | ) | (288 | ) | (20,593 | ) | (14,859 | ) | (4,318 | ) | ||||||||||||
| Net income (loss) | (109,194 | ) | (19,355 | ) | 55,315 | (66,178 | ) | 9,642 | 2,802 | |||||||||||||||
| Basic net income (loss) per share (NIS) | (0.33 | ) | (0.05 | ) | 0.12 | (0.23 | ) | 0.02 | 0.006 | |||||||||||||||
| Diluted net income (loss) per share (NIS) | (0.33 | ) | (0.05 | ) | 0.10 | (0.23 | ) | 0.02 | 0.006 | |||||||||||||||
| Weighted average number of shares outstanding used to compute basic income (loss) per share | 326,651,721 | 377,899,911 | 461,046,640 | 290,794,601 | 437,381,202 | 437,393,465 | ||||||||||||||||||
| Weighted average number of shares outstanding used to compute diluted income (loss) per share | 326,651,721 | 377,899,911 | 538,495,403 | 290,794,601 | 497,489,765 | 497,489,765 |